A robust probiotic strain that enhances intestinal transit, strengthens gut immunity, and supports metabolic wellness.
What it is
Bifidobacterium lactis (Bifidobacterium animalis subsp. lactis) is one of the most widely researched probiotic strains, renowned for its stability and physiological efficacy. Cultured commercially through anaerobic fermentation and stabilized via freeze-drying, it is a key constituent in advanced digestive health supplements. In Velobiotics products, B. lactis utilizes patented MEP microencapsulation, protecting live bacterial cells from gastric destruction and bile degradation to ensure high mucosal survival in the lower intestine.
Also known as: B. lactis, Bifidobacterium animalis subsp. lactis
What it does
- Accelerates gut transit time and relieves constipation.
- Enhances natural immune defenses and antibody response.
- Supports metabolic health and healthy blood lipid profiles.
- Strengthens gut epithelial barrier function.
Amplified by probiotics
Bifidobacterium lactis works in close harmony with lactic acid bacteria like Lactobacillus acidophilus and Lactobacillus rhamnosus. Through active fermentation of dietary fibers, B. lactis releases organic acids that reduce intestinal pH, creating an environment inhospitable to pathogenic microbes. The resulting acetate feeds cross-feeding species like Faecalibacterium prausnitzii, stimulating endogenous butyrate synthesis. Butyrate strengthens intestinal tight junctions and reduces gut permeability, thereby decreasing systemic lipopolysaccharide translocation. Furthermore, B. lactis enhances immune cross-talk by interacting with dendritic cells in Peyer's patches. Velobiotics MEP microencapsulation preserves B. lactis viability through stomach acid, allowing seamless integration into the resident microbiota and boosting overall nutrient utilization.
Typical dose
1–20 billion CFU/day
The evidence
Evidence: strongExtensive clinical evidence validates that Bifidobacterium lactis improves intestinal motility, reduces transit time, and alleviates constipation in adults. Multiple randomized trials also document enhanced antibody responses and reduced incidence of respiratory infections. (Cassís-Nosthas ML 2026, J Vis Exp) (Chen K 2026, Front Nutr) (Beskow CB 2026, Nutr Hosp)
- Cassís-Nosthas ML, et al. Quantification of Changes in Bifidobacteria and Lactobacilli Colony-forming Units During Rifaximin Treatment and Synbiotic Gel in Healthy Volunteers. J Vis Exp. 2026;: PubMed ↗
- Chen K, et al. Efficacy of Bifidobacterium lactis BLa80 in preventing early childhood eczema and respiratory infections via gut microbiome and immune modulation. Front Nutr. 2026;13:1727191 PubMed ↗
- Beskow CB, et al. Analysis of PNPLA3, TM6SF2 and GCKR gene polymorphisms in patients with metabolic dysfunction-associated steatohepatitis treated with probiotics ‒ An exploratory study. Nutr Hosp. 2026;43:561-571 PubMed ↗
Safety & who should check first
Bifidobacterium lactis has an outstanding clinical safety profile and is GRAS-certified for daily human consumption. It is suitable for pregnant and lactating women, with no significant drug interactions reported.